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ABSTRACT 
Objective: In the present investigation, an attempt was made to improve the surface characters and solubility of the drug by solid dispersion and 
coating it on the nonpareil sugar beads as pellets. 
Methods: Ezetimibe solid dispersions were prepared by kneading method using soluplus. Crospovidone was added as a disintegrant in pellets. 
Ezetimibe pellets were prepared by dissolving soluplus and crospovidone in ethanol in different ratios and coated on nonpareil sugar beads as a 
drug layer by pan coating technique. Various physicochemical parameters like particle size, friability, angle of repose and drug content were 
evaluated for the prepared solid dispersions and pellet formulations. In vitro dissolution studies were carried out in 1% SLS using USP apparatus II. 
FTIR and SEM analysis were performed for solid dispersions, pellet formulations and its polymers to determine the interactions and surface 
characteristics. 
Results: The physicochemical parameters were within the specified I. P limits. It was observed that the solid dispersion formulation 
ED5 showed better dissolution rate to the extent of 1.07 folds and 1.95 folds when compared to a marketed formulation and the pure drug, 
respectively. Similarly, pellet formulation EP5 
Conclusion: From the present study, it was observed that the solubility of ezetimibe was enhanced by soluplus in pellet formulations when 
compared to solid dispersions. 
containing 1:5 ratio of ezetimibe to soluplus showed an improved dissolution rate to the extent of 
1.173 folds and 2.136 folds when compared to the marketed formulation and the pure drug, respectively. FTIR analysis revealed that there was no 
major interaction between the drug and the excipients.  
Keywords: Ezetimibe, Soluplus, Crospovidone, HPMC E5, Solid dispersions, Pellets 




Multiparticulate oral drug delivery systems have acquired a center stage 
in the arena of pharmaceutical research and development, thus provide 
greater opportunities in extending the first step of future pharmaceutical 
development. Multiparticulate drug delivery systems include pellets, 
granules, microparticles (like microspheres, microcapsules, 
nanoparticles), mini tablets, mini depots, multiparticulate pulsatile drug 
delivery systems. Pelletized dosage forms date back to the 1950s, when 
the first product was introduced to the market. In 1949, research 
scientists of SmithKline and French developed tiny drug pellets that are 
filled into capsules. Since then, these dosage forms have gained 
considerable popularity because of their distinct advantages such as 
enhancement of drug dissolution; ease of coating with desirable release 
characteristics like sustained, controlled, delayed, site-specific or 
pulsatile delivery of drug from coated pellets; uniform packing; ease of 
capsule filling because of better flow properties due to its spherical 
shape; even distribution in the GI tract and less GI irritation. Pellets are 
obtained from diverse starting materials of fine powders or granules of 
bulk drugs and excipients utilizing different pelletization techniques 
[1]. Pellets intended for oral use are administered in the form of hard 
gelatin capsules or disintegrating tablets which quickly liberate their 
contents in the stomach and gets distributed throughout the 
gastrointestinal tract without loss of the depot effect and acts as self-
contained depots [2, 3]. Pellets are prepared by 
different pelletization techniques like agitation by balling, compaction by 
compression and extrusion-spheronization, layering and globulation by 
spray drying and spray congealing. 
In the present experiment, nonpareil sugar beads were coated with drug 
solution by layering technique. A well-controlled pelletization technique 
in which drug is layered onto starter seed materials which are coarse 
material or nonpareil, in powder, solution or suspension form with the 
aid of binder that assists heterogeneous pellets, consists of an inner core 
region and an outer shell region of a different composition [4, 5]. The 
nonpareil seeds must have spherical shape, smooth surface, the uniform 
particle size distribution for uniform coating [6]. The concentration of 
the binder is based on the choice of the drug because it influences 
physical as well as the mechanical properties of pellets and drug release 
from coated pellets. Commonly used binders include gelatin, povidone, 
carboxymethyl cellulose, hydroxyl propyl methyl cellulose, 
hydroxypropyl cellulose, sodium CMC, maltodextrins. Layering is 
classified into three categories: direct pelletizing, powder layering and 
solution or suspension layering [7, 8]. Materials suitable for use as 
starter cores in the production of coated pellets include sugar spheres 
consisting of saccharides and its derivatives like sugars, sucrose-starch 
mixtures, oligosaccharides and polysaccharides, microcrystalline 
cellulose spheres, pure drug crystals. Polymers which are plastic resins, 
inorganic substances like silica glass, hydroxyapatite and organic 
substances like activated carbon, acids like citric, fumaric, tartaric, 
ascorbic acids etc. can be employed [9]. 
Ezetimibe is a BCS class II drug. It is an antihyperlipidemic drug and 
it helps in lowering the cholesterol [10, 11]. It actually localizes at 
the brush borders of the villi in the small intestine region and 
prevent absorption of the cholesterol from the intestine. It binds to a 
carrier of cholesterol absorption, the Niemann-Pick C1-Like 1 
(NPC1L1) protein on the gastrointestinal tract epithelial cells and 
in hepatocytes thus decreasing the LDL in the body leading to the 
prevention of various life-threatening diseases. It has a poor 
aqueous solubility, which leads to its limited dissolution resulting in 
poor bioavailability (35-65%). 
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The main aim of the present investigation was to formulate 
ezetimibe solid dispersions and fast dissolving pellets by using 
nonpareil sugar beads as inert core material with soluplus as binder 
and solubility enhancer, crospovidone as disintegrant and ethanol 
was used as solvent to prepare the coating suspension to coat on the 
sugar beads as a drug layer by pan coating technique. 
MATERIALS AND METHODS 
Materials 
Ezetimibe was a gift sample from Pellets Pharma Ltd., 
Hyderabad. Soluplus, ethanol and HPMC E5 were procured from SD 
Fine Chem. Ltd., Mumbai. Crospovidone was a gift sample from M/S 
NATCO Pharma Ltd., Hyderabad. 
Preparation of solid dispersions by kneading method 
Methods 
Solid dispersions of ezetimibe in different concentrations of soluplus 
were prepared by kneading method. The required quantities of drug 
and soluplus were dissolved in the solvent ethanol to get a clear 
solution in a dry mortar. The mixture was kneaded for 30 min by 
continuous trituration. Small volume of the solvent was added to 
maintain the mixture as thick slurry during the kneading process. 
Trituration is continued until a dry mass was obtained. The mass 
obtained was further dried at 50 °C for 1 hour in a hot air oven. The 
dried product was powdered and passed through mesh no. 100 in 
each case [12, 13]. Various solid dispersions and their drug to 
carrier ratios are indicated in table 1. 
 
Table 1: Composition of ezetimibe solid dispersions prepared by kneading method using soluplus 
Formulation Composition Drug: Carrier ratio (Ezetimibe: Soluplus) 
ED Ezetimibe: Soluplus 1 1:1 
ED Ezetimibe: Soluplus 2 1:2 
ED Ezetimibe: Soluplus 3 1:3 
ED Ezetimibe: Soluplus 4 1:4 
ED Ezetimibe: Soluplus 5 1:5 
 
Preparation of pellets by pan coating method 
A dispersion of crospovidone in purified water was prepared by 
using half of its quantity and it was initially applied on the sugar 
beads by using spray gun at a pan speed of 300 rpm while 
maintaining the temperature at 60 °C using IR lamp. The 
crospovidone coated beads were further dried at room 
temperature for 12 h. This coat acts as a base coat for applying the 
medicament on the beads. Coating solution was prepared by 
dissolving ezetimibe, soluplus and remaining crospovidone in 
ethanol at different ratios. The crospovidone coated spheres then 
placed in a pan coater and coating solution was sprayed by using 
sprayer gun. Coating pan was operated at 300 rpm, while hot air is 
blown at 50 °C. Then these beads were further dried at room 
temperature for 12 h. The drug-coated beads were finally coated 
with HPMC E5 dissolved in purified water by using a spray gun at 
a pan speed of 300 rpm while maintaining the temperature at 50 
°C using IR lamp. This coat acts as a protective layer and the finally 
coated beads were thoroughly dried in a tray drier at 60 °C for 1 
hour. Then these beads were stored in a desiccator for further use 
[14, 15]. Various pellet formulations and their drug to carrier 
ratios are indicated in table 2. 
 
Table 2: Composition of ezetimibe pellet formulations prepared by pan coating method using soluplus 
Formulation Composition Drug: carrier ratio (Ezetimibe: Soluplus) 
EP Ezetimibe: Soluplus 1 1:1 
EP Ezetimibe: Soluplus 2 1:2 
EP Ezetimibe: Soluplus 3 1:3 
EP Ezetimibe: Soluplus 4 1:4 
EP Ezetimibe: Soluplus 5 1:5 
 
Evaluation of physicochemical parameters on prepared granules 
The physical parameters such as particle size, friability, angle of 
repose and drug content were evaluated for prepared formulations
Particle size determination 
 
as per the standards. 
The average particle size of the prepared solid dispersions and pellet 
formulations was analyzed by sieve analysis method [16]. 
Friability test 
Roche friabilator was used to determine the friability. Pre-weighed 
pellets were placed in friabilator and rotated at a speed of 25rpm for 
4 min. The pellets were then re-weighed after removal of fine and 
the percentage of weight loss was calculated.  
Angle of repose determination 
Angle of repose was determined by passing the solid dispersions and 
pellet formulations through a funnel fixed to a burette stand at a 
particular height (4 cm). A graph paper was placed below the funnel 
on the table. The height and radius of pile were measured [17]. Angle 
of repose of the formulations was calculated using a suitable formula. 




Where h is height and r is the radius of the pile. 
Drug content determination 
Different formulations of ezetimibe equivalent to 10 mg was 
weighed and transferred into a 100 ml volumetric flask. To this, a 
small quantity of methanol was added to dissolve. It was shaken 
occasionally for about 15 min and the volume was made up to 100 
ml by adding 1% SLS. The solution was filtered and the filtrate was 
subsequently diluted with 1% SLS and the absorbance was 
measured at 232 nm using 1% SLS as a blank solution. 
In vitro dissolution studies 
The dissolution test for prepared solid dispersions and pellets was 
carried out in USP apparatus Type II (paddle) with 900 ml of 1% SLS 
as dissolution medium. The temperature and rotations per minute 
(rpm) were maintained at 37±1 °C and 75, respectively. 5 ml 
samples were withdrawn at 5, 10, 15, 20, 30, 45 and 60 min. A fresh 
volume of the medium was replaced with the same volume to 
maintain the sink conditions and the constant volume throughout 
the experiment. The samples withdrawn were suitably diluted with 
same dissolution medium and the amount of drug dissolved was 
estimated by ultraviolet spectrophotometer (UV 3000+) at 232 nm. 
The dissolution studies were carried out for 6 times on all the 
formulations.  
Kunam et al. 
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Based on dissolution data, various dissolution parameters such 
as T50 and DE30% first order constant and Hixon-Crowell constants 
were determined for various formulations. T50 is the time required 
for 50% of the drug to dissolve in suitable dissolution medium. It 
can be measured by plotting a graph taking time in minutes on X-
axis and cumulative percent drug dissolved on Y-axis. The 
dissolution efficiency can have a range of values depending on the 
time intervals chosen. In any case, constant time intervals should be 
chosen for comparison. The index DE30% would relate to the 
dissolution of drug from a particular formulation after 30 min and 
could only be compared with DE30% of other formulations. It was 
calculated using the dissolved percentage curves of the drug versus 
time. Here, the region between the area above the curve and the 
total area of the graph were used for calculation and expressed in 
percentage. 
Characterization of ezetimibe formulations 
Based on the dissolution studies, the optimized formulations were 
selected and FTIR studies were performed to know the drug and 
polymer interactions. SEM analysis was performed for pellet 
formulation and its polymers to know the surface characteristics. 
Accelerated stability studies 
The optimized formulations (ED5 and EP5
RESULTS AND DISCUSSION 
) were subjected to 
accelerated stability studies as per ICH guidelines. They were kept in 
separate petri dishes after preparation and stored in a thermostated 
oven at a temperature and relative humidity (RH) of 25±2 °C, 
60±5% RH for 6 mo and 40±2 °C, 75±5% RH for 3 mo. Then, they 
were evaluated for physical parameters, drug content and drug 
release studies. 
Ezetimibe solid dispersions and fast dissolving pellets were 
prepared by kneading method and spray coating techniques 
respectively. Ezetimibe was formulated as dispersions at different 
concentrations of soluplus; while in pellets, the drug and 
crospovidone concentration was maintained constant. Nonpareil 
sugar beads were used as inert core material for pellet formulation. 
Ethanol was used as a solvent to dissolve the drug and other 
excipients. All the formulations were prepared under identical 
conditions to minimize processing variables. The composition of 
various ezetimibe formulations was given in table 3. 
 
Table 3: Composition of ezetimibe solid dispersions and pellet formulations 
S. No. Ingredients (mg/10 doses) ED ED1 ED2 ED3 ED4 EP5 EP1 EP2 EP3 EP4 5 
1.  Ezetimibe 100 100 100 100 100 100 100 100 100 100 
2.  Sugar Spheres --- --- --- --- --- 1000 1000 1000 1000 1000 
3.  Soluplus 100 200 300 400 500 100 200 300 400 500 
4.  Crospovidone --- --- --- --- --- 25 25 25 25 25 
5.  HPMC E5 --- --- --- --- --- 25 25 25 25 25 
6.  Ethanol q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. q. s. 
7.  Purified Water --- --- --- --- --- q. s. q. s. q. s. q. s. q. s. 
mg = milligram; q. s = quantity sufficient 
 
Evaluation of physicochemical parameters 
Ezetimibe formulations prepared were further evaluated for 
physicochemical parameters such as particle size, friability, angle of 
repose and drug content estimation. All the solid dispersions were 
having the particle size of 245–260 µm, while the pellet formulations 
were found to have the particle size in the range of 835–840 µm. 
Friability loss for all pellet formulations were within the limits 
i.e.<0.8%. Angle of repose values indicated that all solid dispersion 
formulations were having good flow characteristics with an angle of 
repose value ranging from 21–24 °, whereas pellet formulations 
were having excellent flow properties with angle of repose 16–18 °. 
Drug content was estimated for all formulations and found to be 
highly uniform in range of 8.50–9.88 mg/dose. Physicochemical 
parameters evaluated for ezetimibe formulations indicated that all 
formulations were stable and possessing required limits as per 
literature. The values of physicochemical parameters of ezetimibe 
formulations were given in table 4. 
  
Table 4: Evaluation of physicochemical parameters of ezetimibe formulations 




Angle of repose( °) Drug content (mg/dose) 
mean±SD 
1.  ED1 250±0.12 ---- 24 8.50±0.12 
2.  ED2 255±0.46 ---- 23 9.11±0.21 
3.  ED3 260±0.39 ---- 23 9.18±0.19 
4.  ED4 260±0.27 ---- 22 9.21±0.26 
5.  ED5 245±0.36 ---- 21 9.32±0.38 
6.  EP1 835±0.28 0.2 18 9.38±0.32 
7.  EP2 840±0.52 0.2 18 9.58±0.26 
8.  EP3 835±0.48 0.1 17 9.68±0.42 
9.  EP4 835±0.38 0.12 17 9.75±0.36 
10.  EP5 840±0.29 0.12 16 9.88±0.28 
 n=3; µm=micrometer; %w/w= percentage weight by weight; SD= Standard deviation 
 
Dissolution studies were conducted for all the ezetimibe fast 
dissolving formulations along with pure drug and the marketed 
formulation. Dissolution studies were performed by using USP 
apparatus type II (paddle type) with 1% SLS as a medium, while 
maintaining bath temperature at 37±1 °C with a paddle operated at 
75 rpm. Dissolution profiles indicated that ezetimibe pure drug 
released to the extent of 46.53% whereas the marketed formulation 
(Ezedoc 10) was released to the extent of 84.72% at one hour. Solid 
dispersions EDIn vitro dissolution studies 1–ED5 found to release the drug in the range of 61.53 
to 90.90%. The prepared fast dissolving solid dispersions tend to 
increase drug release from 1.322 to 1.953 folds when compared to 
pure drug. Pellet formulations EP1-EP5 were found to release the 
drug from 63.23 to 99.41%. These fast dissolving pellet formulations 
tend to increase the drug release from 1.358 to 2.136 folds when 
compared to pure drug and 1.07 to 1.173 folds when compared to 
the marketed formulation. It was observed that the dissolution rate 
of the solid dispersion formulation ED5 showed better dissolution 
rate to the extent of 1.072 folds and 1.953 folds when compared to 
Kunam et al. 
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the marketed formulation and pure drug respectively. Similarly, 
formulation EP5 containing 1: 5 ratio of ezetimibe to soluplus the 
dissolution rate was increased to the extent of 1.173 folds when 
compared to the marketed formulation and 2.136 when compared to 
pure drug. It was observed that the rate of dissolution is greatly 
increased with pellet formulations than compared to solid 
dispersions prepared. Formulation EP5 pellets containing 1:5 drug 
to polymer ratio exhibited better release characteristics when 
compared to formulation ED5
  
 containing 1:5 ratio of drug and 
polymer. This was due to the increased surface area of the pellet 
formulations [18, 19]. Other studies also showed that use of 
soluplus as the carrier in solid dispersions and pellet 
formulations enhanced the solubility and hence the 
bioavailability of BCS Class-II drugs. [20, 21] Results of the 
present study also justified the same. Dissolution profiles were 
given in fig. 1 and 2. 
 
Fig. 1: Dissolution profiles of ezetimibe fast dissolving solid dispersions (Results are expressed as mean±SD, n=3) 
 
 
Fig. 2: Dissolution profiles of ezetimibe fast dissolving pellets (Results are expressed as mean±SD, n=3) 
 
Dissolution parameters such as T50 and DE30% values were 
calculated for all the formulations. T50 for solid dispersions range 
from 13 to 34 min. Similarly, T50 for pellet formulation ranges from 
12 to 31.5 min. DE30% values for solid dispersions ranges from 35 to 
48.33%. DE30% values for pellet formulations ranges from 35.00 to 
53.43%. Majority of the formulations displayed first order release 
kinetics and were found to be linear with R2 values in the range of 
0.874 to 0.982. The Hixon crowell constants for all the formulations 
were found to be linear with R2
 
 values ranging from 0.952 to 0.997 
indicating that the drug release is by continuous depletion of the 
drug from the film formed across the spherical bead per unit weight. 
The results were indicated in table 5. 
Table 5: In vitro dissolution kinetics of ezetimibe formulations 
S. No. Formulations T50 DE (min) 
(%) 
30 First order Hixon crowell 
R K2 1 (min-1 R) K2 HC (mg1/3) 
1 Pure drug  25 0.874 0.009 0.958 0.004 
2 Marketed formulation (Ezedoc 10) 15 43.3 0.966 0.028 0.994 0.012 
3 ED 34 1 35 0.896 0.013 0.978 0.006 
4 ED 23 2 36.66 0.899 0.015 0.952 0.007 
5 ED 19.5 3 38.33 0.929 0.019 0.963 0.008 
6 ED 17.5 4 45 0.924 0.022 0.984 0.009 
7 ED 13 5 48.33 0.969 0.034 0.991 0.014 
8 EP 31.5 1 35 0.907 0.014 0.992 0.006 
9 EP 23 2 41.6 0.929 0.018 0.961 0.008 
10 EP 20 3 44.2 0.956 0.021 0.997 0.01 
11 EP 14 4 51.66 0.963 0.031 0.991 0.013 
12 EP 12 5 53.43 0.982 0.042 0.992 0.024 
 T50= Time required for 50% of drug release; DE30=Dissolution efficiency within 30 min; R2= Regression coefficient; K1= First order rate constant; 
KHC= Hixon crowell rate constant 
Kunam et al. 





The drug and excipient interactions were further characterized by IR 
Spectral analysis. FTIR Spectra of ezetimibe pure drug, soluplus, 
optimised ezetimibe solid dispersion and optimized ezetimibe pellet 
formulation were obtained by KBr pelletization process. Spectra 
exhibited peaks, indicating the presence of =C-H,-C-F and C=O, 
stretching and bending functional groups. Thus the FTIR Spectral 
analysis indicated that there were no drug interactions. The detailed 




Fig. 3: FTIR interpretation of ezetimibe 
 
 
Fig. 4: FTIR interpretation of soluplus 
 
 
Fig. 5: FTIR spectra of optimized solid dispersion (ED5) 
Kunam et al. 




Fig. 6: FTIR spectra of optimized pellet formulation (EP5) 
 
Table 6: FTIR spectrum interpretation for ezetimibe formulations 
Functional group Wave number (cm-1) 
Pure drug Soluplus ED5 EP5 
C-H Stretching 3133.85 3101.99 3111.62 3125.21 
C=O Stretching 1718.01 1638.19 1618.06 1638.19 
C-H Bending 1510.01 1411.36 1407.84 1406.3 
C-F Stretching, aromatic 851.77 --- 819.51 866.67 
 
SEM analysis 
The SEM analysis revealed the structure of ezetimibe as crystalline 
and soluplus as spherical which were indicated in fig. 8. Solid 
dispersions prepared by kneading technique were found to be in the 
fine amorphous form of dispersion where drug is totally entrapped 
into soluplus. The uncoated and coated sugar beads exhibited a 
smooth surface with a uniform coating upon the coated pellets, 
thereby providing improved surface area for better dissolution rate. 
 











Fig. 8: Scanning electron microscopic images of (a) ezetimibe 
(b) soluplus, (c) solid dispersions (d) sugar spheres (e) coated 
spheres 
Kunam et al. 
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Accelerated stability studies 
The optimized formulations ED5 and EP5
 
 were subjected to 
accelerated stability studies as per ICH guidelines after storage at 
different conditions. Physical parameters and drug release studies 
were carried out on these formulations and the results were 
indicated in table 7 and fig. 9, 10 respectively. 
Table 7: Parameters of formulations ED5 and EP5
Formulation 
 under accelerated stability conditions 





Angle of repose ( °) Drug content (mg/dose) 
mean±SD 
ED Before Storage 5 245±0.36 ---- 21 9.32±0.38 
25±2 °C, 60±5% RH 245±0.34 ---- 21 9.29±0.22 
40±2 °C, 75±5% RH 245±0.32 ---- 22 9.27±0.39 
EP Before Storage 5 840±0.29 0.12 16 9.88±0.28 
25±2 °C, 60±5% RH 840±0.26 0.11 16 9.86±0.21 
40±2 °C, 75±5% RH 840±0.21 0.11 17 9.84±0.26 
n=3; RH = Relative humidity; SD= Standard deviation 
 
 
Fig. 9: Drug release studies of ED5
 
 before and after storage at different Conditions (Results are expressed as mean±SD, n=3) 
 
Fig. 10: Drug release studies of EP5
 
 before and after storage at different conditions (Results are expressed as mean±SD, n=3) 
There was no significant change observed in physical parameters 
and drug release even stability studies at various storage conditions 
and indicated that these formulations were found to be stable. 
CONCLUSION 
Ezetimibe solid dispersions and fast dissolving pellet formulations were 
prepared by using soluplus as a fast dissolving carrier. Among the 
various formulations prepared formulation ED5and EP5 
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